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Description 
Benign or premalignant skin lesion removal/destruction 
Policy Type 
Local medical necessity policy 
Indications and Limitations of Coverage and/or Medical Necessity 
G0051 
Medicare 8 will consider the destruction of a benign or premalignant skin lesion medically 
necessary under the following circumstances: 
• When the patient presents with an actinic keratosis that has changed in size, has developed 
erythema, has thickened, has ulcerated, has eroded, has developed changes at the tumor 
margins, has become markedly hyperkeratotic, in which pain has developed and/or a 
cutaneous horn has developed; 
• When the patient presents with an actinic keratosis on the nose, ear, or eyelids; 
• When the patient presents with a actinic keratosis and has a history of one of the following: 
- chronic immunosuppression such as that associated with organ transplantation, 
particularly renal transplantation, and other disease processes such as Human 
Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) and/or 
chronic lymphocytic leukemia or lymphoma; 
- treatment of psoriasis with psolaren-ultraviolet A (PUVA) therapy; 
- xeroderma pigmentosum, albinism, or discoid lupus erythematosus; 
and/or, 
previous treatment of a biopsy-proven Squamous Cell Carcinoma (SCC) or other 
skin malignancy. 
• When the patient has multiple actinic keratoses and has self-administered 2% to 5% 
Fluorouracil (Efudex) topical cream for two to four weeks and the actinic keratoses have not 
responded to this treatment one to two months following treatment*, or 
* It should be noted that the natural response to fluorouracil (Efudex) is erythema, usually . / 
followed by vesiculation, desquamation, erosion and reepithelialization. Therefore, during 
and immediately following fluorouracil treatment these signs and symptoms would be 
considered part of the response/healing process and would not be considered as meeting 
the criteria for removal. There are contraindications for the use of topical fluorouracil which 
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include pregnancy, use on mucous membranes, use on mouth, and use around eyes or on 
nose. If after two months, the actinic keratoses have not responded, they may be removed 
or destroyed. 
• When the patient presents with an actinic cheilitis (actinic keratosis of the lower lip) or an 
actinic keratosis of the upper lip; 
• When the patient presents with an actinic conjunctivae (actinic keratosis on the bulbar 
conjunctivae); 
• When a patient presents with an arsenical keratosis (due to arsenic exposure); 
• When a patient presents with a keratosis and has a history of significant exposure to 
therapeutic or occupational radiation therapy (chronic radiation keratosis); and/or 
• When a patient presents with a keratosis which arises from an old scar ( chronic cicatrix 
keratosis). 
If none of the aforementioned conditions exist, Medicare B of Florida would consider the 
removal of an actinic keratosis as medically unnecessary and, therefore, not reimbursable by 
Medicare. 
In addition, chemical or cryogenic peels of the face, even in the presence of actinic keratoses, 
are considered medically unnecessary in nature because the technique is used to improve the 
appearance of photodamaged skin, and is, therefore, not reimbursable by Medicare. 
The total number of services billed utilizing procedure codes G0051, G0052, and G0053 which 
exceed the number that would be considered medically necessary and reasonable accordingto 
established parameters will be reviewed on a prepayment basis using the criteria in this section 
of the policy. 
Generally, the removal of benign lesions such as seborrheic keratoses, sebaceous cysts, and -
warts are done for cosmetic reasons, however, in rare instances it may be necessary to remove 
these types of lesions. Medicare B of Florida will consider the removal of these lesions as 
medically necessary for any of the following reasons: 
• the lesion is in an area such as the neck, bra line or waist and is constantly irritated and/or 
is located in an anatomical location of recurrent trauma and that such trauma has in fact 
occurred; 
• the lesion obstructs an orifice or clinically obstructs vision (this would include any lesion); 
• the patient presents with condylomata acuminata (venereal warts) and/or is 
immunosuppressed; and/or, 
• plantar warts or other lesions on the sole of the foot which impede the patient s ability to 
ambulate or which meet any of the aforementioned criteria. 
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If the aforementioned signs and symptoms are not present, further treatment would be 
considered medically unnecessary and, therefore, not reimbursable by Medicare 8-of Florida. 
Destruction of benign or premalignant lesions that exceed utilization parameters as determined 

















Destruction by any method, including laser, with or without surgical curettement of all 
benign or premalignant lesions (e.g., actinic keratosis), other than skin tags or 
cutaneous vascular proliferative lesions, including local anesthesia; initial lesion 
second through 14 lesions, each (G0051 plus G0052 equal 14 lesions) 
15 lesions or more (includes G0051 and G0052; that is, G0053 may not be 
reported in addition to G0051 and G0052)] 
Shaving of epidermal or dermal lesion, single lesion, trunk, arms, or legs; lesion 
diameter 0.5 cm or less 
lesion diameter 0.6 to 1.0 cm 
lesion diameter 1.1 to 2. 0 cm 
lesion diameter over 2.0 cm 
Shaving of epidermal or dermal lesion, single lesion, scalp, neck, hands, feet, 
genitalia; lesion diameter 0.5 cm or less 
lesion diameter 0.6 to 1.0 cm 
lesion diameter 1. 1 to 2. 0 cm 
lesion diameter over 2.0 cm 
Shaving of epidermal or dermal lesion, single lesion, face, ears, eyelids, nose, lips, 
mucous membrane; lesion diameter 0.5 cm or less 
lesion diameter 0.6 to 1.0 cm 
lesion diameter 1.1 to 2. 0 cm 
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lesion diameter 0.6 to 1.0 cm 
lesion diameter 1.1 to 2. 0 cm 
lesion diameter 2.1 to 3.0 cm 
lesion diameter 3.1 to 4.0 cm 
lesion diameter over 4.0 cm 
Excision, benign lesion, except skin tag (unless listed elsewhere), scalp, neck, 
hands, feet, genitalia; lesion diameter 0.5 cm or less 
lesion diameter 0.6 to 1.0 cm 
lesion diameter 1.1 to 2.0 cm 
lesion diameter 2.1 to 3. 0 cm 
lesion diameter 3.1 to 4.0 cm 
lesion diameter over 4.0 cm 
Excision, other benign lesion (unless listed elsewhere), face, ears, eyelids, nose, 
lips, mucous membrane; lesion diameter 0.5 cm or less 
Excision, benign lesion, except skin tag (unless listed elsewhere), trunk, arms or 
legs; lesion diameter 0.5 cm or less 
lesion diameter 0.6 to 1.0 cm 
lesion diameter 1.1 to 2.0 cm 
lesion diameter 2.1 to 3.0 cm 
lesion diameter 3.1 to 4. 0 cm 
lesion diameter over 4.0 cm 
Destruction by any method of flat warts or molluscum contagiosum, milia, up to 15 
lesions 
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17999 Unlisted procedure, skin, mucous membrane, and subcutaneous tissue 
ICD-9 Codes That Support Medical Necessity 
N/A 
HCPCS Section and Benefit Category 
lntegumentary System, Surgery 
HCFA National Coverage Policy 
Medicare Carrier's Manual (MCM) 4826 
Reasons for Denial 
G0051 
Benign skin lesions and premalignant skin lesions (actinic keratosis) removals which do not 
meet the criteria as outlined in "Indications and Limitations" are considered medically necessary 
and will not be reimbursed by Medicare B or Florida. 
Noncovered ICD-9 Code(s) 
N/A 
Sources of Information 
Medicare Carrier s Manual 
Physicians Current Procedure Terminology (CPT) 1996 
American Academy of Dermatology, Inc. (1995). Guidelines of Care for Actinic Keratosis. 
Journal of the American Academy of Dermatology, 32, 95-98. 
Chiarello, S. E. (1992). Full-face Cryo- (Liquid Nitrogen) Peel. Journal of Dermatology 
Surgical Oncology. 18, 329-332. 
Drake, L., Ceilly, R., Cornelison R., Dobes, W., Dorner, W., Goltz R., Lewis, C., Calasche, S., & 
Chanco Turner, M. (1992). Guidelines of Care of Nevi I (NevOcellular Nevi and Seborrheic 
Keratosis). Journal of the American Academy of Dermatology, 26(4), 629-631. 
Eighty-five Percent of Patients with Actinic Keratosis Cured in Hyal Drug Trial. (1994, 
October). Cancer Researcher Weekly. 
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Environmental Protection Agency, (1987). Ultravio-:et Radiation and Melanoma, with a special 
focus on assessing the risks of strataspheric ozone depletion. Washington, DC: Office of 
Air and Radiation. 
Fitzpatrick, T., Eisen, A., Wolff, K., Freedburg, I., & Austen, K. (Eds.). (1993). Dermatology in 
General Medicine (Vol. 1). New York: McGraw Hill, Inc. 
Johnson, M, Rowe, D., Nelson, B., & Swanson, N. (1992). Squamous Cell Carcinoma of the 
Skin (Excluding Lip and Oral Mucosa). Journal of the American Academy of Dermatology, 
26(3), 467-480. 
Kibarian, M. & Hruza, G. (1995). Nonmelanoma Skin Cancer: Risks, Treatment Options, and 
Tips on Prevention. Post Graduate Medicine, .9.8(6), 39-49. 
Kuflik, A. & Schwartz, R. (1994). Actinic Keratosis and Squamous Cell Carcinoma. American 
Family Physician, 49(4), 16-19. 
Kwa, R., Campana, K., & Moy, R. (1992). Biology of Cutaneous Squamous Cell Carcinoma. 
Journal of the American Academy of Dermatology, 26, 1-20 . . 
Lawrence, N., Cox, S., Cockerell, C., Freeman, R., and Cruz, P. (1995). A Comparison of the 
Efficacy and Safety of Jessner's Solution and · 35% Trichoroacetic Acid vs. 5% Fluorouracil 
in the Treatment of Widespread Facial Actinic Keratoses. Archives of Dermatology. 131. 
176-181. 
Li, J. & Ackerman, A.B., "Seborrheic Keratosis" that Contain Human Papilloma-virus Are 
Condylomata Acuminata. The American Journal of Dermatopathology, 16,(4), 398-405. 
Maize, J. & Snider, R. (1995). Nonmelanoma Skin Cancers in Association with Seborrheic 
Keratoses. Dermatology Surgery, 21, 960-962. 
Marks, R. & Motley, R., (1995). Skin Cancer Recognition and Treatment. Drugs, 50(1 ), 48-61. 
Marks, R. (1991). The Role of Treatment of Actinic Keratoses in the Prevention of Morbidity 
and Mortality due to Squamous Cell Carcinoma. Archives of Dermatology. 127, 1031-
1033. 
Melloni s Illustrated Medical Dictionary (2nd ed.). 1985. Baltimore, MD: Williams and Wilkins. 
Patterson, J. (1993). Squamous cell carcinoma. Tumors of Epidermal and Follicular Origin, 
~.21 :21, 1-16. 
Physicians' Desk Reference, 1996. Efudex Brand of Fluorouracil Topical Solutions and 
Creams. 2113-2114. 
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Preston, D., & Stern, R. (1992). Nonmelanoma Cancers of the Skin. The New England 
Journal of Medicine, 327, (23), 1649-1662. 
Tierney, L., McPhee, S., & Papadakis, M. (Eds.). (1996). Current Medical Diagnosis & 
Treatment (35th ed.). 
Coding Guidelines 
G0051 
CPT coding is based on the type of lesion (benign or premalignant), method of destruction or 
removal, and the number of lesions removed for any of the procedure codes within the following 
ranges: 11300-11313; 11400-11446; 17110; 17999; or G0051-G0053. 
If a lesion is destroyed or removed for any reason other than one listed under the "Indications 
and Limitations" section of this policy, the procedure is considered medically unnecessary and 
is, therefore , not reimbursable by Medicare and should be billed utilizing procedure code A9270 
(noncovered service) . 
Modifier -24 is used for unrelated evaluation and management services by the same physician 
during the postoperative period. 
Modifier -25 is used to indicate that on the day a procedure was performed, the patients 
condition required a significant separately identifiable evaluation and management service. 
Procedure code G0051 and G0053 may only be billed once per day. Procedure code G0052 
may be billed no more than thirteen (13) times in one day because the descriptor reads "2nd 
through fourteen (14) lesions, each lesion". It is not appropriate to use modifier -76 (repeat 
procedure) with these codes. 
Procedure code G0053 includes G0051 and G0052. Therefore, it it not appropriate to bill 
procedure code G0053 on the same day as G0051 and G0052 for the same patient by the 
same provider. 
When the patient is seen for purposes of prescribing fluorouracil and providing instruction on 
how to use this medication, the appropriate level of evaluation and management service may 
be reimbursed. 
Documentation Requirements 
If the patient presents with an actinic keratosis(es) and its appearance has changed, i.e., size: 
erythema, thickening, ulceration, and/or erosion in the tumor or tumor margins or if the patient 
has developed pain within the lesion, this should be clearly documented in the physician s 
progress/office note to substantiate removal of the lesion. 
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If the patient presents with an actinic keratosis(es) and has a history of chronic 
immunosuppression; treatment of psoriasis with PUVA therapy; xeroderma pigmentosum, 
discoid lupus erythematosus or albinism; and/or a previous treatment of a biopsy-proven sec, 
this should clearly be documented in the physician s progress/office note. The approximate 
starting date and duration of radiation therapy or PUVA therapy should be· documented, if 
applicable. In addition, the date of organ transplantation should be documented, if applicable. 
Any other immunosuppressive disorder should be documented with the date or approximate 
date of diagnosis. 
If the patient presents with multiple actinic keratoses, the self-administration of topical 2% to 
5% fluorouracil (Efudex) cream or solution for a period of no less than two weeks and 
unresponsiveness to the drug after two months should be documented. If the patient has a 
condition in which fluorouracil is contraindicated such as pregnancy or actinic keratosis(es) 
around the eyes, on the nose, on the mouth, or on mucous membranes, the physician's 
office/progress note should reflect this. The location of this lesion(s) should be documented in 
the office/progress note as well. 
If the patient presents with an actinic cheilitis (actinic keratosis of the lower lip) or an actinic 
keratosis on the ear or conjunctiva, the exact location and a description of the lesion s 
appearance should be documented in the physician s progress/office note. 
Also, if the patient has had a previous biopsy-proven sec or other skin malignancy, the 
location of that lesion, the date of removal, and a pathology report for the previous lesion, if 
available, should be documented. In addition, for the aforementioned conditions/treatments, 
the exact location and a description of the lesion should be documented. 
For cicatrix keratoses, the location of the scar, the type of the scar, the approximate date the 
scar developed, and a description of the size, location and appearance of the lesion should be 
documented in the physicians progress/office note. 
Although not required at this time, a photograph of the lesion with an indication of the size and 
location would be an excellent documentation tool for the size, location, and appearance of the 
lesion. If the physician is not able to take a photograph or make a sketch in his/her notes 
regarding size, location, and appearance of the lesion, a very clear description of the lesion 
must be included in the progress/office note. 
For those benign lesions that are located in areas which subject the lesion to constant 
irritation and/or trauma and need to be removed because of constant or frequent 
traumatization, the exact location and size of the lesion and type of irritation and/or trauma 
should be documented in the physician s progress note/office note. 
In addition, to the above, the method of destruction or removal should be described in 
the physician s progress/office note for any type of lesion destroyed or removed. 
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Other Comments 
G0051 
Kuflik and Schwartz (1994) describe actinic keratosis as a scaly, cutaneous lesion caused 
by chronic sun exposure which appears as an adherent, keratotic (circumscribed 
overgrowth of the horny layer of the epidermis) that is often seen in elderly patients and 
usually develops on the face, ears, and dorsa of the hands. Because histologic changes in 
the epidermis associated with these lesions may progress to Squamous Cell Carcinoma (SCC), 
these lesions are considered premalignant. The authors state that "induration, erythema, or 
erosion of actinic keratoses may be indicative of progression to squamous cell carcinoma. It is 
believed that several years can elapse before this transformation occurs. Up to one (1) percent 
of patients with untreated actinic keratosis have been reported to develop" SCC (Kuflik and 
Schwartz, 1994). Moreover, the authors state "the tumor that develops is usually slow-growing, 
with little tendency to metastasize". 
Kibarian and Hruza (1995) state that the most common premalignant lesion is actinic keratosis 
and about one in six Americans will develop at least one in their lifetime, however, they also 
contend that only one percent of all actinic keratoses progress to SCC which supports the 
statistic cited by Kuflik and Schwartz, 1994. Conversely, in the Cancer Reseacher Weekly, 
(October 31, 1994), it is estimated that up to 10% progress to SCC. However, only 0.3% to 
3. 7% of cutaneous secs metastasize (Kwa et. al., 1992). 
Marks (1991) estimates the incidence of SCC as 481 per 100,000, however, 40% of these do 
not arise from preexisting actinic keratosis. Accordingly, Marks suggests that the metastasis 
rate of SCC arising from an existing actinic keratosis is very low and, although, a number of 
people die from SCC each year, many of these deaths are not attributable to previously 
untreated actinic keratosis. Marks claims that the secs tend to occur in immunosuppressed 
patients and elderly men who have neglected high risk areas such as the lower lip (actinic 
cheilitis). 
According to Marks, "treating the very large proportion of the community who have Actinic 
Keratoses and who do not fall into these categories may not necessarily prevent many of the 
deaths due to SCC at present", however, it is suggested that any suspicious actinic keratosis be 
. investigated and treated. Marks contends that there is some doubt based on the present data 
as to whether treating all actinic keratoses will lead to a reduction in morbidity and mortality 
associated with SCC. 
According to Marks and Motley, (1995) fluorouracil cream is a useful treatment for actinic 
keratoses. Furthermore, they assert that these solar keratoses are "cosmetically annoying" but 
do concede that the presence of these keratoses indicates marked solar damage in that area of · 
the skin from which more serious lesions may arise. They also support the contention that ,. 
squamous cell lesions on the genitalia, the lips and the ear have a higher risk of metastasis 
than do other squamous cell lesions in other areas. 
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According to the Ph1sicians' Desk Reference (PDR), multiple actinic keratoses and keratoses 
not located on mucous membranes, the nose or mouth Q[ on or around the eye, can be treated 
with 2% to 5% fluorouracil (Efudex) cream or solution for a period of two to four weeks. 
Moreover, the PDR states that complete healing of the lesion may take up to two months. The 
cream or solution may be applied by the patient and is, therefore, considered a self-
administered medication by Medicare B. The PDR recommends that actinic keratoses not 
responsive to fluorouracil should be biopsied to confirm the diagnosis. 
In a study which compared the efficacy and safety of Jessner's Solution and 35% 
Trichloroacetic Acid with 5% Fluorouracil, fifteen (15) male subjects with multiple actinic 
keratoses on each side of the face were selected to participate. Each patient was treated with 
Jessner's Solution and 35% Trichloroacetic Acid on the left side for three (3) weeks. "Without 
exception, all patients demonstrated a marked reduction in the number of Actinic Keratoses" 
following treatment. "Both the fluorouracil and the chemical peel induced almost identical 
percent reductions (75% in the number of Actinic Keratoses" (Lawrence, N., Cox, S., Cockerell, 
C., Freeman, R., and Cruz, P., 1995). 
The authors go on to say that medium-depth chemical peeling, such as that done with 
Jessner's Solution and 35% Tricholoracetic Acid, was of interest not only because of its 
therapeutic potential, but for its cosmetic benefits as well. In addition, they say that topical 
fluorouracil cream applied twice daily for 3 weeks has long been the standard of treatment for 
widespread Actinic Keratoses. They also stated that, based on patient questionnaires, only two 
(2) patients complained of pain due to the chemical peel whereas four (4) patients complained 
of pain from fluorouracil. They state, "Our results show that 5% fluorouracil cream and 
Jessner's solution plus 35% tricholoracetic acid are equally effective at eliminating AK based on 
clinical and histologic parameters." The authors further state, "Although the cost of a full-face 
peel (reimbursed by Medicare at $200) is higher than the cost of purchasing the two to three 
tubs of 25g 5% fluorouracil cream required" for full treatment time which "retails for $100 to 
$120, single office-application and reduced extent and duration of morbidity (erythema from 
peel lasting 2 weeks and erythema lasting up to six weeks with the fluorouracil) make the peel 
more desirable for widespread AK. 
According to the American Academy of Dermatology (1995), actinic keratoses are mainly due to 
long-term sun exposure and may progress to sec. According to the Academy s "Guidelines of 
care for actinic keratosis", it is believed that approximately 60% of all susceptible adults, i.e., 
fair-skinned persons who sunburn easily and tan poorly, those who are occupationally-exposed 
to the sun, and those who participate in outdoor hobbies and sports, will have at least one 
actinic keratosis after the age of 40. The Academy s guidelines cite the features which may 
suggest progression to SCC which are induration, erythema, erosions, pain in the lesion, 
hyperkeratosis, and/or increasing diameter. Furthermore, actinic keratoses can be diagnosed / 
clinically, but a biopsy may be indicated to verify diagnosis or exclude underlying malignancy. · 
Due to the high incidence of actinic keratoses, the Academy recommends that all practitioners 
should provide efficacious, cost-effective care such as chemical destruction, cryosurgery, or 
curettage. However, laser surgery is recommended for actinic cheilitis. 
November 25, 1996 10 
CPT codes, descriptions, and 2-digit numeric modifiers only are copyright, 1991 AM..\. All Rights Reserved. 
Medicare Part B 
Medical Policy Procedures 
BENIGN OR PREMALIGNANT SKIN LESION REMOVAUDESTRUCTION G0051 
"Actinic keratoses are considered premalignant, but only 1: 1000 lesions per year progress to 
become squamous cell carcinoma" (Tierney et. al., 1996). Furthermore, "the frequency of 
metastasis is not precisely known, though metastatic spread is said to be less likely with 
squamous cell carcinoma arising out of actinic keratoses than with those that arise de nova". 
De novo indicates SCC developing from normal-appearing skin. The text states that "in 
actinically-induced squamous cell cancers, rates of metastasis are estimated from retrospective 
studies to be 3 - 7%". However, "squamous cell carcinomas of the lip, oral cavity, tongue, and 
genitalia deserve special care and management". Another estimate of squamous cell 
carcinoma metastasis is 2% to 6% (Kibarian, et. al., 1995). However, Kwa et. al., 1992, states 
that the metastatic rate for de nova sec has been reported at rates of 7. 7% to 17 .3%. 
Actinic Keratosis (also called solar keratosis or senile keratosis) and actinic cheilitis may be 
viewed as "a squamous cell carcinoma grade ½, ¾, or grade 1" on Broder s classification scale 
for sec (cited in Dermatology in General Medicine, 4th ed.). This means that the microscopic 
changes of sec are present in part or all of the epidermis and remain confined to it. According 
to the text, "older age, blue eyes and childhood freckling correlate with increased risk of actinic 
keratosis" and "effects over 50% of the elderly fair skinned persons in hot sunny climates". 
Others who are susceptible to actinic keratoses and SCCs are renal transplant patients and 
other immuno-compromised individuals. Again, the suspicion of progression to a sec is 
described as induration, erythema, erosion, or increasing diameter. According to the text, 
actinic cheilitis "usually presents as a diffuse slight scaling of the entire lower lip to the 
commissures" and if an erosion appears, "one must be concerned about the possibility of 
invasive SCC, although invasion may manifest without ulceration" (cited in Dermatology in 
General Medicine, 4th ed.). 
Johnson et. al. (1992) claims that an estimated maximum of 5% to 20% of actinic keratoses 
develop into SCCs in 1 O to 25 years. Actinic keratosis is felt to be a good marker to indicate the 
skin type and amount of sun exposure that may lead to skin cancer. In addition, Johnson et. al. 
( 1992) contends that the propensity to develop invasive sec with a higher metastatic rate is 
greater in those keratoses originating from long-term radiation exposure and scars. Moreover, 
the authors state that the majority of SCCs are small, low-risk tumors and have a high cure rate 
with conventional therapeutic measures such as curettage and electrodessication, cryosurgery, 
and surgical excision (Johnson, et. al., 1992). 
According to the authors, there are several precursor lesions to SCC. These include actinic 
keratoses; arsenical keratoses (lesions that arise from exposure to arsenic); thermal 
keratoses (lesions that result from thermal damage secondary to exposure to infrared 
light and most commonly arise in erythema abigne); chronic radiation keratoses [lesions 
that result from long-term exposure to electromagnetic wave radiation (usually x-rays)]; 
tar keratoses (lesions that result from exposure to aromatic hydrocarbons); chronic 
cicatrix keratoses (lesions that may develop from scars after many years); Bowens 
disease (lesions that are considered a form of sec in situ); erythroplasia of Queyrat 
November 25, 1996 11 
CPT codes, descriptions, and 2-digit numeric modifiers only are copyright, 199 l AMA. All Rights Reserved. 
i 
·t-f 
Medicare Part B 
Medical Policy Procedures 
BENIGN OR PREMALIGNANT SKIN LESION REMOVAUDESTRUCTION G0051 
(lesions that are generally seen on the glans penis and are considered a form of sec in 
situ); and lesions that occur in patients with EV, or Lewandowsky-Lutz syndrome, which 
is a~ familial disease that presents as widespread macules and papules that contain 
at least 15 different Human Papilloma Virus (HPV) types in childhood. 
According to Johnson, et. al., (1992), "the propensity to develop into an invasive sec with a 
higher metastatic potential is greater with chronic radiation and chronic cicatrix (scar) 
keratoses" while "thermal and tar keratoses have a low biologic potential but may evolve into 
invasive SCC". As stated earlier, according to the authors, an estimated 5% to 20% of actinic 
keratoses may evolve into SCC in 10 to 25 years. Also, Johnson, et. al., 1992, state that "the 
annual incidence rate of SCC is 0.24% for each actinic keratosis" and "as many as 25% of 
actinic keratoses may spontaneously remit in some patients, particularly during periods of 
decreased sun exposure", however, they warn "even in these patients, new lesions develop 
more frequently than those undergoing remission". Also, the authors contend that "60% of 
sec arose from a preexisting actinic keratosis diagnosed within the previous year". 
According to Preston and Stern (1992), SCC in situ, also referred to as Bowens Disease, is 
usually a single red, scaling plaque or nodule that is often sharply demarcated. Invasive sec 
arising from an actinic keratosis is said to be much less malignant than invasive SCC arising 
from Bowen s Disease, or erythroplasia of Queyrat, or from premalignant lesions such as a 
radiation or scar keratosis (cited in Dermatology in General Medicine, 4th ed.). However, both 
actinic keratosis and Bowen s disease may persist for years before becoming invasive (Preston 
and Stern, 1992). While actinic keratoses are the most common precancerous skin lesion, they 
are considered benign but bear histopathologic similarities to Bowen s Disease (Kwa et. al., 
1992). 
"The typical invasive SCC arising from an actinic keratosis may be subtle and difficult to 
distinguish from the scaly, erythematous patch that represents its precursor. Keratoses that 
become markedly hyperkeratotic" (describes an overgrowth of the horny layer of the skin) 
"or indurated or undergo spontaneous ulceration are likely examples of SCC" (Patterson, 1993). 
The development of a cutaneous horn is probably a hypertrophic actinic keratosis, however, it is 
recommended that a representative sample including its base is necessary to prove or disprove 
invasive sec (Dermatology in General Medicine, 4th ed.). A shave biopsy including the base is 
not only diagnostic, but usually curative as well. In addition, actinic keratoses where full-
thickness dysplasia, i.e., differentiation toward the interface with the stratum corneum, has 
occurred, it is considered bowenoid actinic keratoses, a type of in situ sec (Dermatology in 
General Medicine, 4th ed.). Therefore, if this were suspected, a biopsy of the lesion would be 
appropriate to rule out sec. 
Approximately 1 per 1000 actinic keratoses and Bowen s disease (SCC in situ) per year 
progress to invasive cancer. Indications for treatment include the onset of symptoms or recent 
substantial growth. "Whether treating all actinic keratoses to prevent squamous-cell carcinoma 
is justified remains controversial." (Preston and Stern, 1992). 
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"Arsenic, once an ingredient in many medicinal potions and still a component of insecticides, 
causes a distinctive palmar and plantar keratosis that are associated with a high risk of 
squamous cell carcinoma" (Preston and Stern, 1992). 
Keracanthomas occur primarily on sun-damaged skin in the elderly. According to Preston and 
Stern (1992), they begin as "red, dome shaped papules that expand rapidly and develop a 
central crater filled with a keratinous plug". Most keracanthomas regress for months without 
therapy, however, some are aggressive and metastasize (Preston and Stern, 1992). For this 
reason, the authors suggest that it would be prudent to treat a "suspect keracanthoma as 
cancer". Therefore, biopsy of this lesion may be appropriate. 
While areas of lower latitude are mentioned in many literature sources as a factor in increasing 
UVB levels (Johnson, et. al., 1992; Patterson, 1993; ), other factors such as altitude and low 
annual precipitation may also effect UVB levels. This is clearly demonstrated by the fact that 
Albuquerque, New Mexico has a higher UVB index and geographically has a higher latitude and 
altitude than New Orleans, Louisiana, however, the National Institute of Health (NIH) 
Publication No. 83-2433 (1983) stated that the annual age-adjusted incidence of cutaneous 
secs for 1977-1978 was 154 per 100,000 white men in New Orleans and 180 per 100,000 in 
Albuquerque (as cited in the Dermatology in General Medicine, 4th ed., 1993). This fact is 
further supported by the 1987 Environmental Protection Agency (EPA) publication which 
demonstrates in Figure 14-1 the increased rate of UVB radiation in Albuquerque over that of 
such cities as New Orleans, Atlanta, San Francisco, and Detroit. Unfortunately, no information 
is provided for Florida but the fact that Florida is at a lower latitude and the entire state is at a 
lower altitude than New Mexico, one would expect that New Mexico s utilization of these codes 
would be in line with that of Florida s. It is of note that Albuquerque is situated slightly above 35 
latitude versus Louisiana, Florida and most of Texas and Georgia which are all situated below 
this mark. 
According to 1989 Surveillance, Epidemiology and End Results (SEER) data downloaded from 
the Centers for Disease Control (CDC) Wonder database, Florida ranked 7th at a rate of 4.14 
per 100,000 of persons aged 65 and older in "other malignant neoplasms of the skin" (diagnosis 
codes 173 through 173.9). 
This excluded malignant melanoma and carcinoma in situ. New Mexico was ranked 2nd at a 
rate of 5.03 per 100,000 of persons aged 65 and older. Surprisingly and in contradiction to the 
theory that latitude plays the only significant role geographically, Ohio was ranked 3rd and 
Illinois 4th. Following are the utilization per 1000 of procedure code 17000, 17001, and 17002 
[Medicare B Extract System (BESS) database, January through June 1995] for the top ranked 
states for diagnosis codes 173 through 173.9. 
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According to January through June 1995 data retrieved from the Cadman Research Group, Inc. 
Pandora software, using specialty group 07 (Dermatology) and "Excision Benign Skin Lesions" 
as the case type, it was determined that for this specialty group and case type, 17000, 17001, 
and 17002 were the top three procedure codes by allowed services. Moreover, actinic 
keratosis (diagnosis code 702.0) was the diagnosis used almost 50% of the time for this 
specialty and case type. 
In addition to the aforementioned, the top counties for that time period, i.e., those where the 
number of observed services exceeded the number of expected services, were as follows: St. 
Johns, Flagler, Indian River, Martin, Palm Beach, Broward, Collier, Charlotte, Sarasota, and 
Manatee counties. All counties are coastal counties, however, St. Johns and Flagler counties 
are located in northeast Florida. Because Dade county which is south of Brevard had less 
observed services than expected, based on the Cadman data, and Monroe county which 
includes the Keys and is south of Collier county, demonstrated no significant difference in the 
observed services to expected services, further information regarding demographics for these 
areas would be helpful. 
According to Medicare s provider base data, as of April 1995, those counties had the following 
numbers of dermatologists out of a total of 522 for the entire state: 
C_OUNTY NO. OF DERMATOLOGISTS % FOR STATE 
St. Johns 3 ~.6% 
Flagler 1 ~.2% 
Indian River 5 ~1% 
Martin 3 ~.6% 
Palm Beach 51 -10% 
Broward 82 -16% 
Collier 12 ~2% 
Charlotte 4 <1% 
Sarasota 18 3.4% 
Manatee 6 1.1% 
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OTHER DEFINITIONS AND INFORMAT!ON: 
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In epidermodysplasia verruciforms, an autosomal recessive disorder, "flat wafts infected 
with human papillomavirus" (HPV) "especially subtypes 5 and 8, commonly undergo malignant 
degeneration to squamous cell carcinoma in young patients" (Preston and Stern, 1992). 
However, the authors go on to say that whether eradicating HPV infection would reduce the risk 
of SCC has not been established. Furthermore, for HPV to induce nonmelanoma skin cancer, 
the authors suggest that additional consideration of factors such as ultraviolet radiation, 
decreased cellular immunity, and/or genetic predisposition are probably required. Kwa et. al. 
(1992) categorize epideromodysplasia verruciforms as a disorder which causes 
immunosuppression. 
Seborrheic keratoses are "extremely common benign neoplasms that usually appear in 
the skin of middle-aged and older adults" (Li and Ackerman, 1994). They are further 
described as "well-circumscribed, brown and slightly raised papules with smooth, 
mammillated, or verrucous" (covered with wartlike roughness) "surfaces topped by 
scales" (Li and Akerman, 1994). 
IN SUMMARY: 
Florida is ranked second nationally in the utilization of procedure code 17000 per 1000 
beneficiaries compared with other carriers per 1000 beneficiaries. Florida dermatologists 
utilization of 17001 and 17002 exceeds the utilization of their peers in all other states when 
comparing services per 1000 beneficiaries. Actinic keratosis (diagnosis code 702.0) is the most 
common diagnosis used with these procedure codes in Florida. 
Actinic keratoses are the most common precancerous lesions among light-complected 
individuals in the United States. These lesions have been referred to as benign (Kwa et. al. , 
1992) to carcinoma in situ (Patterson, 1993). However, most clinicians refer to these as 
premalignant. Clinically, these lesions may evolve into sec, however, the opinions on the 
occurrence of that range frqm 1 % (Kuflik and Schwartz, 1994; Kibarian et. al., 1995) to a 
maximum of 20% (Johnson, et. al., 1992) In addition, only 2% to 7% of these actinically-
derived secs may metastasize (Kibarian et. al., 1995; Tierney et. al., 1996). 
Furthermore, the states which had reported higher incidences of "other malignant neoplasms of 
the skin" (diagnosis codes 173 through 173.9) have less utilization of procedure codes 17000, 
17001, and 17002 than does Florida per 1,000 beneficiaries. 
Therefore, it has been determined that Medicare B of Florida will allow reimbursement for the 
diagnosis 702.0 (actinic keratosis) only under certain circumstances and will only rarely allow 
reimbursement for the removal of benign lesions as listed in the "Indications and Limitations" 
section of this policy. 
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Rationale for Creating Policy 
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Florida statistical data for January through June 1995 demonstrated that Florida's utilization per 
1,000 beneficiaries of procedure codes 17000-17002 significantly exceeded national utilization 
per 1,000 beneficiaries by several specialties. Following causal analysis, it was determined that 
the top diagnosis code was diagnosis code 702.0 (Actinic Keratosis); therefore, a literature 
review was performed to determine whether all actinic keratoses should be removed and 
general information regarding benign skin lesions. This local medical review (LMRP) 
represents all benign or premalignant skin lesion removal/destruction procedure codes and has 
been separated from the LMRP related to malignant lesion removal/destruction codes. 
Policy has been updated to include the 1997 HCPCS and MPFSDB changes. 
CAC Notes 
This policy does not reflect the sole opinion of the Carrier or Carrier Medical Director. 
Conversely, this policy was presented and discussed with the medical community via the 
Carrier Advisory Committee on July 20, 1996. 
Start Date of Comment Period: 07/20/96 
Start Date of Notice Period: 
Original Effective Date: 
Revised Effective Date: 
Revision Number: 5 
Revision History: 
Start Date of Comment Period: 07/20/96 
Start Date of Notice Period: 
Original Effective Date: 
Revised Effective Date: 
Revision Number: 4 
Start Date of Comment Period: N/A 
Start Date of Notice Period: N/A 
Effective Date: 
Revision Date: 
Revision Number: 3 
Start Date of Comment Period: N/A 
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This policy does not reflect the sole opinion of the carrier or Carrier Medical Director. 
Conversely, this policy was developed in consultation with the medical community via the 
Carrier Advisory Committee on July 31, 1993, which includes representatives from the Surgical 
and Medical Communities. 
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